Raloxifene, a new selective estrogen receptor modulator

Journal of Clinical Pharmacology

Volumn 39, Issue 8, 1999, Pages 767-774

  Goldfrank, D ^a   Haytoglu, T ^a   Frishman, W H ^a   Mohammad, Z ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RALOXIFENE; TAMOXIFEN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; DEEP VEIN THROMBOSIS; DRUG EFFICACY; ESTROGEN ACTIVITY; HUMAN; LIPOPROTEIN METABOLISM; NONHUMAN; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK ASSESSMENT; THROMBOEMBOLISM; UTERUS CANCER;

EID: 0033306818     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922008416     Document Type: Review

References (67)

1. Postmenopausal estrogen therapy and cardio-vascular disease
2. Clinical pharmacology of estrogens: Focus on their cardiovascular actions and cardioprotectire benefits of replacement therapy in postmenopausal women
3. Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
4. Clinical review 27: Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women
5. Estrogen effects on cognition in menopausal women
6. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia
7. Menopause and hormone replacement therapy: An overview
8. Benefits and risks of estrogen replacement therapy
9. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
10. Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats
11. Raloxifene, an 'antiestrogen,' simulates the effects of estrogen on inhibiting bone resorption through regulating TGFβ-3 expression in bone
12. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women
13. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
14. Tissue-selective actions of estrogen analogs
15. Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid Composition
16. Tamoxifen use, oestrogen binding and serum lipids in postmenopausal women with breast cancer
17. Serum cholesterol reduction with tamoxifen
18. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal post-menopausal women
19. Tamoxifen in the treatment of breast cancer
20. Agonistic and antagonistic effects of antiestrogens in different target organs
21. Designer oestrogens: Fact or fantasy?
22. Effects of a new anti-estrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels
23. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
24. Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifene and 9-cis-retinoic acid
25. Molecular basis of agonism and antagonism in the oestrogen receptor
26. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens
27. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene
28. Hormonal treatment of postmenopausal women
29. Antioxidant potential of specific estrogens on lipid peroxidation
30. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-Up Study
31. Post-menopausal use of estrogen and occlusion of coronary arteries
32. Effects of raloxifene on serum lipids and coagulation factors in healthy post menopausal women
33. Raloxifene favorably alters serum lipids in postmenopausal women with cardiovascular risk factors
34. Effects of raloxifene and hormone replacement therapy on homocysteine and c-reactive protein levels in postmenopausal women
35. Raloxifene inhibits aortic accumulation of cholesterol in ovarectomized, cholesterol-fed rabbits
36. Lack of effect of raloxifene on coronary artery atherosclerosis of post menopausal monkeys
37. Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL)
38. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment
39. Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in post-menopausal women
40. Tamoxifen decreases cholesterol sevenfold and aboliSheS lipid lesion development in apolipo-protein E knockout mice
41. Effect of tamoxifen on serum cholesterol and lipoproteins during chemohormonal therapy
42. Administration of long-term tamoxifen therapy modifies the plasma lipoprotein-lipid concentration and lipid transfer protein I activity in postmenopausal women with breast cancer
43. Symptoms associated with tamoxifen treatment in postmenopausal women
44. Contrasting effects of conjugated estrogens and tamoxifen on dilator responses of atherosclerotic epicardial coronary arteries in nonhuman primates
45. Hormones as cardiovascular drugs: Estrogens, progestins, thyroxine, growth hormone, corticosteroids, and testosterone
46. Risk Of venous thromboembolism in users of hormone replacement therapy
47. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
48. Effects of raloxifene in postmenopausal women (correspondence)
49. The decision to enter a randomized trial of tamoxifen for the prevention of breast cancer in healthy women: An analysis of the tradeoffs
50. Venous thrombosis as a side effect of tamoxifen treatment
51. Raloxifene regulates thrombomodulin and plasminogen activator inhibitor-1 in human endothelial cells
52. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model
53. Raloxifene reduces the risk of breast cancer and may decrease the endometrial cancer in post menopausal women: Two year findings from the Multiple Outcome of Raloxifene Evaluation (MORE) Trial (abstract)
54. A pharmacological review of raloxifene
55. Antagonism of estrogen action with a new benzothiophene derived antiestrogen
56. Raloxifene preserves bone strength and bone mass in ovarectomized rats
57. The effects of raloxifene on tibia histomorphometry in ovariectomized rats
58. Effects of raloxifene hydrochloride on serum markers of bone and lipid metabolism: Dose-response relationships
59. A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women
60. Raloxifene and estrogen: Comparative bone remodeling kinetics
61. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
62. Hormone replacement therapy and heart disease prevention: Experimentation trumps observation
63. Women's Health Initiative Study Group: Design of the Women's Health Initiative Clinical Trial and Observational Study
64. Of designer drugs, magic bullets and gold standards
65. SERMS: The benefits of estrogen without risks?
66. Selective estrogen receptor modulators: A controversial approach for managing postmenopausal health
67. Selective estrogen receptor modulators: A look ahead